New Foundation Aims to Speed Type 1 Diabetes Research Into Clinical Trials

Type 1 diabetes researchers have long known that transplanting insulin-producing cells from donors could restore the body's ability to make insulin. However, this approach has come with a major drawback: the immune system recognizes the transplanted cells as foreign and attacks them. To prevent this rejection, patients must take immunosuppressive drugs for life—medications that carry significant risks including increased susceptibility to infection, higher cancer rates, and kidney failure.

Now, a new foundation backed by private donors is accelerating research into a potential solution to this problem. Professor Per-Ola Carlsson at Uppsala University has developed a method that genetically modifies insulin-producing cells to make them invisible to the immune system, potentially eliminating the need for long-term immunosuppressive therapy.

Carlsson's research gained attention this past summer when the New England Journal of Medicine published results from a pioneering study. The work involved modifying insulin-producing cells through three specific genetic steps designed to remove the cell properties that trigger immune rejection.

Notably, this was the first study of its kind conducted in a patient. The results showed that the genetically modified cells functioned as intended, suggesting the method has potential to become a curative treatment for type 1 diabetes. While early-stage research in a single patient cannot determine whether a treatment will work broadly, these findings represent an important proof of concept.

The newly established foundation was created by Anders Eriksson and Mats Gustafsson, two private individuals with finance backgrounds who each have a child with type 1 diabetes. Their donations are specifically intended to support the next phase of Carlsson's research.

According to Carlsson, the foundation's support will help move the research forward more rapidly. "This is a very welcome initiative that will help us get our planned clinical trials up and running faster, as soon as two to three years from now," he said. Larger clinical trials will be essential to determine whether this approach is safe and effective across a broader population of people with type 1 diabetes.

Origin: uu.se (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.